Skip to main content

anti-epcam/anti-4-1bb bispecific antibody bnt314

Generic: Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314

anti-epcam/anti-4-1bb bispecific antibody bnt314: 2 clinical trials tracked.

anti-epcam/anti-4-1bb bispecific antibody bnt314 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-epcam/anti-4-1bb bispecific antibody bnt314, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Metastatic Colorectal Cancer
Clinical Trial Registry Records (2)

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer

NCT07079631Registry updated 2026-07-01·Phase 1/Phase 2·BNTX
Recruiting

Primary endpoint: Phase I - Part A: Occurrence of dose limiting toxicities (DLTs) during the DLT observation period

InterventionalRandomizedopen482 targetStarted 2025-07Completion 2032-1214 sites · Germany, Japan, Spain, United Kingdom…BioNTech SE

A First-in-Human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of BNT314 as Monotherapy in Patients With Advanced Malignant Solid Tumors

NCT06150183Registry updated 2026-09-15·Phase 1·BNTX
Active, not recruiting

Primary endpoint: Occurrence of dose-limiting toxicity within a cohort

Interventionalopen41 enrolledStarted 2023-11Completion 2026-1114 sites · Belgium, Denmark, Japan, Spain…BioNTech SE